The CF Foundation recently provided an update on the following research trial.
Vertex 661 and ivacaftor (VX-661-108) in people with cystic fibrosis with one copy of the F508del-CFTR mutation and a second CFTR mutation with a gating defect responsive to Ivacaftor
This is a Phase 3, multi-center trial that will look at the safety and effectiveness of the drug VX-661 in combination with ivacaftor. Researchers will test the drug’s effectiveness by measuring participant’s lung function, sweat chloride, and other outcome measures. This trial is for people ages 12 years and older with one copy of the F508del-CFTR mutation and a second CFTR Gating Mutation shown to respond to the drug ivacaftor. The trial will last approximately 3 months. It will require blood draws, sweat tests and lung function tests.
- CFF Link: https://tools.cff.org/Display/dsp_ClinicalResearchHTML.cfm?id=406&IDH=9153423
- ClinicalTrials.gov Link: https://www.clinicaltrials.gov/ct2/show/NCT02412111